Bluejay DiagnosticsBJDX
Market Cap: 3.45M
About: Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.
Employees: 10
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
42% more capital invested
Capital invested by funds: $243K [Q4 2023] → $345K (+$101K) [Q1 2024]
29% more funds holding
Funds holding: 7 [Q4 2023] → 9 (+2) [Q1 2024]
18.47% more ownership
Funds ownership: 16.09% [Q4 2023] → 34.57% (+18.47%) [Q1 2024]
Research analyst outlook
We haven’t received any recent analyst ratings for BJDX.